중동 및 아프리카 신경내분비 종양 시장, 분류(기능적 네트 및 비기능적 네트), 부위(폐, 췌장, 위장관(GI), 등급(등급 1{저등급 종양}, 등급 2{중간등급 종양}, 등급 3{고등급 종양}), 유형(진단 및 치료), 투여 경로(경구 및 비경구), 구매 방식(처방 및 일반의약품(OTC)), 최종 사용자(병원, 전문 병원, 방사선 센터, 가정 의료 및 기타), 유통 채널(직접 입찰, 병원 약국, 소매 약국, 온라인 약국 및 기타), 국가( 남아프리카 , 사우디 아라비아, UAE, 이집트, 이스라엘, 쿠웨이트 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 2028년까지의 예측
시장 분석 및 통찰력 : 중동 및 아프리카 신경내분비종양 시장
신경내분비종 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 9.3%의 CAGR로 성장하고 있으며 2028년까지 1억 7,412만 달러에 도달할 것으로 예상한다고 분석했습니다. 시장 참여자의 전략적 이니셔티브와 신경내분비종에 대한 대량 예방 접종 프로그램의 출현은 예측 기간 동안 시장 수요를 촉진한 주요 원동력이 될 가능성이 높습니다.
종양의 시작은 건강한 세포의 DNA가 손상되어 세포가 통제할 수 없는 방식으로 변화하고 성장하여 응집된 세포 덩어리를 형성할 때 발생합니다. 종양은 암성일 수도 있고 양성일 수도 있습니다. 악성 암성 종양은 조기에 발견하여 치료하지 않으면 자라서 신체의 다른 부분으로 퍼집니다. 양성 종양은 자랄 수 있지만 퍼지지 않습니다. 양성 종양은 일반적으로 최소 침습 수술을 사용하여 많은 해를 끼치지 않고 제거할 수 있습니다. 신경내분비 종양(NET)은 신체의 신경내분비계의 특수 세포에서 시작됩니다. 이 세포는 호르몬을 생성하는 내분비 세포와 신경 세포의 공통적인 특성을 가지고 있습니다. 이들은 신체 기관 전체에서 발견되며 신체의 많은 기능을 제어하는 역할을 합니다. 모든 NET는 악성 종양으로 간주됩니다. 대부분의 NET는 수년이 걸려 천천히 발달하고 성장합니다.
그러나 치료와 관련된 부작용, 충족되지 않은 요구, 여러 지역의 의료 자원 접근성, 높은 진단 비용과 같은 요인이 신경내분비종양 시장의 성장을 방해하고 있습니다. 반면에 다가올 표적 치료와 시장 참여자 간의 증가하는 파트너십과 협력은 신경내분비종양 시장의 성장을 위한 기회로 작용합니다. 신경내분비종양 약물 개발에 대한 환불 정책의 부족과 엄격한 정부 규정은 신경내분비종양 시장이 직면한 과제입니다.
신경내분비종양 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
신경내분비종양 시장 범위 및 시장 규모
신경내분비종 시장은 분류, 부위, 등급, 유형, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 분류 에 따르면 신경내분비종양 시장은 기능성 그물과 비기능성 그물로 세분화됩니다. 2021년에는 비기능성 그물 세그먼트가 식별 및 진단의 용이성과 비기능성 그물을 제거하기 위한 새로운 진단 방법의 사용으로 인해 신경내분비종양 시장을 지배하고 있습니다.
- 신경내분비종 시장은 부위에 따라 폐 , 췌장 및 위장관(GI)으로 세분화됩니다. 2021년에는 위장관(GI) 세그먼트가 위암 유병률 증가로 인해 신경내분비종 시장을 지배하고 있으며 강력한 제품 파이프라인이 시장을 지배할 것으로 예상됩니다.
- 등급에 따라 신경내분비종양 시장은 등급 1(저등급 종양), 등급 2(중간등급 종양), 등급 3(고등급 종양)으로 세분화됩니다. 2021년에는 등급 2(중간등급 종양) 세그먼트가 신경내분비종양 시장을 지배하고 있는데, 이는 치료적 치료법으로 쉽게 치료할 수 있고 등급 2(중간등급 종양) 사례가 증가할 것으로 예상되기 때문입니다.
- 신경내분비종 시장은 유형을 기준으로 진단 과 치료로 세분화됩니다. 2021년에는 췌장암 종양의 발병률이 증가하고 시장에서 자동화된 진료 시점 진단이 확대됨에 따라 진단 부문이 신경내분비종 시장을 지배할 것으로 예상됩니다.
- 투여 경로에 따라 신경내분비종 시장은 경구 및 비경구로 세분화됩니다. 2021년에는 경구 세그먼트가 경구 형태의 약물 가용성, 더 큰 환자 준수 및 흡수 용이성으로 인해 신경내분비종 시장을 지배할 것으로 예상됩니다.
- On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others. In 2021, hospitals segment is expected to dominate the neuroendocrine tumors market due to the availability of diagnostics machines to detect neuroendocrine tumor with the availability of healthcare policies.
- On the basis of distribution channel, the neuroendocrine tumors market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is expected to dominate the neuroendocrine tumors market due to rise of suppliers in the market.
Neuroendocrine Tumors Market Country Level Analysis
The neuroendocrine tumors market is analysed and market size information is provided classification, site, grade, type, route of administration, end user and distribution channel as referenced above.
The countries covered in the neuroendocrine tumors market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and rest of Middle East and Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services. South Africa is expected to dominate in the Middle East and Africa region due to technological advancements for the detection of neuroendocrine tumors.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Government Initiatives and the Rising Collaborations by Market Players are creating new Opportunities in the Neuroendocrine Tumors Market
Neuroendocrine tumors market also provides you with detailed market analysis for every country growth in particular industry with neuroendocrine tumors sales, impact of advancement in the neuroendocrine tumors and changes in regulatory scenarios with their support for the neuroendocrine tumors market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Neuroendocrine Tumors Market Share Analysis
신경내분비종양 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 신경내분비종양 시장과 관련된 회사의 초점에만 관련이 있습니다.
신경내분비종 시장의 주요 기업으로는 Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline plc, Thermo Fisher Scientific Inc., Hutchison China MediTech Limited, F. Hoffmann-La Roche Ltd, Bionano Genomics, Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Merck & Co., Inc.의 자회사, Sun Pharmaceutical Industries Ltd., Illumina, Inc., LUPIN 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 제품 출시와 계약을 체결하면서 신경내분비종 시장도 활성화되고 있습니다.
예를 들어,
- 2018년 1월 , Novartis AG는 Novartis AG의 자회사인 Advanced Accelerator Applications가 성인의 전장, 중장 및 후장 신경내분비 종양을 포함한 소마토스타틴 수용체 양성 위장관췌장 신경내분비 종양(GEP-NET) 치료를 위한 신약 신청 Lutathera(루테튬 Lu 177 도타테이트*)에 대한 FDA 승인을 받았다고 선언했습니다. 회사가 받은 FDA 승인으로 임상 시험이 증가하고 신경학 분야에서 종양학 제품 포트폴리오가 강화되었으며 시장에서 긍정적인 성장을 가져올 것입니다.
시장 참여자의 협력, 합작투자 및 기타 전략은 신경내분비종양 시장에서 회사 시장을 확대하고 있으며, 이를 통해 조직이 치료에 대한 제공 내용을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASSIFICATION LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 PRICING ANALYSIS
7 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: REGULATIONS
7.1 REGULATORY PROCEDURE IN THE U.S.
7.2 REGULATORY PROCEDURE IN CANADA
7.3 REGULATORY PROCEDURE IN EUROPE
7.4 REGULATORY PROCEDURE IN CHINA
7.5 REGULATORY PROCEDURE IN MIDDLE EAST AND AFRICA
8 COMPARITIVE ANALYSIS BETWEEN MONOCLONAL AND POLYCLONAL ANTIBODY
8.1 MONOCLONAL ANTIBODY
8.2 POLYCLONAL ANTIBODY
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASED INCIDENCE OF NEUROENDOCRINE TUMOR CASES
9.1.2 TECHNOLOGICAL ADVANCEMENT FOR THE DETECTION OF NEUROENDOCRINE TUMORS
9.1.3 GROWTH IN THE NUMBER OF PRIVATE DIAGNOSTIC CENTERS AND TREATMENT PROVIDERS
9.1.4 PRESENCE OF TARGETED TREATMENT OPTIONS
9.1.5 FAVORABLE REIMBURSEMENT POLICIES
9.2 RESTRAINTS
9.2.1 HIGH CAPITAL INVESTMENTS & LOW BENEFIT-COST RATIO FOR BIOMARKERS AND ORPHAN DRUGS
9.2.2 LACK OF AWARENESS AMONG THE POPULATION
9.2.3 UNMET NEEDS AND ACCESS TO MEDICAL RESOURCES IN SEVERAL REGIONS
9.2.4 HIGH COST OF DIAGNOSIS
9.3 OPPORTUNITIES
9.3.1 INCREASED GOVERNMENT INITIATIVES
9.3.2 EMERGING THERAPIES & DEVELOPMENT IN TREATMENT
9.3.3 RISING COLLABORATIONS AMONG THE MARKET PLAYERS
9.4 CHALLENGES
9.4.1 SIDE EFFECTS ASSOCIATED WITH TREATMENTS
9.4.2 STRINGENT GOVERNMENT REGULATIONS FOR THE DEVELOPMENT OF NEUROENDOCRINE TUMOR DRUGS
10 IMPACT OF COVID 19 ON MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET
10.1 PRICE IMPACT
10.2 IMPACT OF DEMAND
10.3 IMPACT ON SUPPLY CHAIN:
10.4 STRATEGIC DECISIONS:
10.5 CONCLUSION:
11 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION
11.1 OVERVIEW
11.2 NON-FUNCTIONAL NET
11.3 FUNTIONAL NET
12 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE
12.1 OVERVIEW
12.2 GASTROINTESTINAL TRACT (GI)
12.3 LUNGS
12.4 PANCREAS
13 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE
13.1 OVERVIEW
13.2 GRADE 2 (INTERMEDIATE-GRADE TUMOR)
13.3 GRADE 3 (HIGH-GRADE TUMOR)
13.4 GRADE 1( LOW-GRADE TUMOR)
14 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE
14.1 OVERVIEW
14.2 DIAGNOSIS
14.2.1 BLOOD TEST
14.2.2 IMAGING TEST
14.2.2.1 CTSCAN
14.2.2.2 MRI
14.2.2.3 OTHERS
14.2.3 BIOPSY
14.2.4 URINE TEST
14.2.5 OTHERS
14.3 TREATMENT
14.3.1 SOMATOSTATIN ANALOGS
14.3.1.1 OCTREOTIDE
14.3.1.2 LANREOTIDE
14.3.2 TARGETED THERAPY
14.3.2.1 EVEROLIMUS
14.3.2.2 SUNITINIB
14.3.2.3 OTHERS
14.3.3 RADIATION THERAPY
14.3.3.1 EXTERNAL-BEAM RADIATION
14.3.3.2 INTERNAL-BEAM RADIATION
14.3.4 SURGERY
14.3.4.1 CHOLECYSTECTOMY
14.3.4.2 OTHERS
14.3.5 LIVER-DIRECTED TREATMENT
14.3.5.1 RADIO FREQUENCY ABLATION (RFA)
14.3.5.2 HEPATIC ARTERY EMBOLIZATION
14.3.5.3 RADIOEMBOLIZATION
14.3.6 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)/ LUTATHERA
15 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLETS
15.2.2 PILLS
15.2.3 OTHERS
15.3 PARENTERAL
15.3.1 SUBCUTANEOUS
15.3.2 INTRAMUSCULAR
15.3.3 OTHERS
16 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALITY CLINICS
16.4 RADIATION CENTERS
16.5 HOME HEALTHCARE
16.6 OTHERS
17 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 HOSPITAL PHARMACY
17.4 RETAIL SALES
17.5 ONLINE PHARMACY
17.6 OTHERS
18 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GEOGRAPHY
18.1 MIDDLE EAST AND AFRICA
18.1.1 SOUTH AFRICA
18.1.2 SAUDI ARABIA
18.1.3 EGYPT
18.1.4 ISRAEL
18.1.5 UAE
18.1.6 KUWAIT
18.1.7 REST OF MIDDLE EAST AND AFRICA
19 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
20 SWOT
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 BRISTOL-MYERS SQUIBB COMPANY
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 COMPANY SHARE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENTS
21.4 THERMO FISHER SCIENTIFIC INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 REGENERON PHARMACEUTICALS, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENTS
21.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 BIONANO GENOMICS
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 BIOSYNTHEMA INC.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 CALLISTOPHARMA
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENTS
21.11 ELI LILLY AND COMPANY
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENTS
21.12 EXACT SCIENCES CORPORATION
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 GLAXOSMITHKLINE PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 HUTCHISON CHINA MEDITECH LIMITED
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 IPSEN PHARMA
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 ILLUMINA, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENTS
21.17 LUPIN
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANALYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENTS
21.19 PFIZER INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENTS
21.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 TEVA PHARMACEUTICAL INDUSTRIES LTD.
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS
TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020
TABLE 3 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, COUNTRY, 2021-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 44 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION
TABLE 48 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)
TABLE 56 MIDDLE EAST ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 58 MIDDLE EASTA AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )
TABLE 61 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 94 EGYPT EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 95 EGYPT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 96 EGYPT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 97 EGYPT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 98 EGYPT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 99 EGYPT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 100 EGYPT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 101 EGYPT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 102 EGYPT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 103 EGYPT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 104 EGYPT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 105 EGYPT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 106 EGYPT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 107 EGYPT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 108 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 109 EGYPT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 110 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 111 ISRAEL EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 112 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 113 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 114 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 115 ISRAEL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 116 ISRAEL IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 117 ISRAEL TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 118 ISRAEL SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 119 ISRAEL TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 120 ISRAEL RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 121 ISRAEL SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 122 ISRAEL LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 123 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 124 ISRAEL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 125 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 126 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 127 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 128 UAE EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 129 UAE NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 130 UAE NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 131 UAE NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 132 UAE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 133 UAE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 134 UAE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 135 UAE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 136 UAE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 137 UAE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 138 UAE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 139 UAE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 140 UAE NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 141 UAE ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 142 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 143 UAE NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 144 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 145 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
TABLE 146 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)
TABLE 147 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)
TABLE 148 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 149 KUWAIT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 150 KUWAIT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 151 KUWAIT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 152 KUWAIT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 153 KUWAIT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 154 KUWAIT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 155 KUWAIT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 156 KUWAIT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)
TABLE 157 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 158 KUWAIT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 159 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
TABLE 160 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)
TABLE 161 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
TABLE 162 REST OF MIDDLE EAST AND AFRICA EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SEGMENTATION
FIGURE 11 INCREASED AWARENESS OF NEUROENDOCRINE TUMORS CASES IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 NON-FUNTIONAL NET SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET IN 2021 & 2028
FIGURE 13 FIVE YEAR SURVIVAL RATE OF PANCREATIC NEUROENDOCRINE TUMOR BETWEEN 2010- 2016
FIGURE 14 INCIDENCE OF NEO-ENDOCRINE NEOPLASM IN CHINA, EUROPE AND U.S.
FIGURE 15 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, 2020
FIGURE 16 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2020-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY SITE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2020-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY SITE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY SITE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY GRADE, 2020
FIGURE 24 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2020-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY GRADE, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY GRADE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY TYPE, 2020
FIGURE 28 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2020-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY ROUTE OF ADMINSTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY END USER, 2020
FIGURE 36 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2020-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: SNAPSHOT (2020)
FIGURE 44 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2020)
FIGURE 45 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: BY CLASSIFICATION (2021-2028)
FIGURE 48 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
